Ye Qidong, Ying Qianqian, Dai Qiaoyan, Liao Cong, Xiao Gang
Department of Pediatrics, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, No. 59 Liuting Street, Ningbo, 315000, Zhejiang Province, People's Republic of China.
Funct Integr Genomics. 2023 Jan 19;23(1):43. doi: 10.1007/s10142-022-00950-9.
MicroRNA (miR)-381-3p is the newly discovered tumor-associated miRNA, which is frequently associated with diverse human malignancies; but, it is still unknown about its effect on acute myeloid leukemia (AML) in children. This work focused on exploring miR-381-3p's effect on childhood AML and identifying the possible mechanisms facilitating new treatment development. Using qRT-PCR analysis, miR-381-3p expression remarkably reduced in pediatric AML patients and AML cell lines (HL-60 and U937). Following transfection of miR-381-3p mimic or inhibitor into HL-60 and U937 cells, we conducted MTT assay to evaluate cell proliferation, flow cytometry (FCM) to measured cell apoptosis and cell cycle, whereas Transwell assays to detect cell invasion and migration. Our results demonstrated that miR-381-3p overexpression remarkably repressed cell growth, invasion and migration; additionally, miR-381-3p overexpression resulted in arrest of cell cycle and enhanced cell apoptosis. In contrast, miR-381-3p knockdown led to an opposite effect. Moreover, we predicted miR-381's target gene and validated it by luciferase reporter assay and TargetScan, separately. We identified miR-381-3p's binding site in ROCK1 3'-UTR. As revealed by Western-blot (WB) assay, miR-381-3p overexpression notably suppressed ROCK1 level. Moreover, restoring ROCK1 expression abolished miR-381-3p's inhibition on cell proliferation, invasion and migration. Data in this work indicated the role of miR-381-3p as the tumor suppressor within pediatric AML by targeting ROCK1. Therefore, miR-381-3p might serve as a potential therapeutic target for the treatment of pediatric AML.
微小RNA(miR)-381-3p是新发现的与肿瘤相关的微小RNA,常与多种人类恶性肿瘤相关;但其对儿童急性髓系白血病(AML)的影响尚不清楚。本研究聚焦于探索miR-381-3p对儿童AML的影响,并确定其可能的作用机制,以促进新的治疗方法的开发。通过qRT-PCR分析发现,miR-381-3p在小儿AML患者及AML细胞系(HL-60和U937)中的表达显著降低。将miR-381-3p模拟物或抑制剂转染至HL-60和U937细胞后,我们进行MTT试验以评估细胞增殖,采用流式细胞术(FCM)检测细胞凋亡和细胞周期,同时通过Transwell试验检测细胞侵袭和迁移能力。我们的结果表明,miR-381-3p过表达显著抑制细胞生长、侵袭和迁移;此外,miR-381-3p过表达导致细胞周期停滞并增强细胞凋亡。相反,miR-381-3p敲低则产生相反的效果。此外,我们分别通过荧光素酶报告基因试验和TargetScan预测并验证了miR-381的靶基因。我们确定了miR-381-3p在ROCK1 3'-UTR中的结合位点。蛋白质免疫印迹(WB)分析显示,miR-38l-3p过表达显著抑制ROCK1水平。此外,恢复ROCK1表达可消除miR-381-3p对细胞增殖、侵袭和迁移的抑制作用。本研究数据表明,miR-381-3p通过靶向ROCK1在小儿AML中发挥肿瘤抑制作用。因此,miR-381-3p可能成为治疗小儿AML的潜在治疗靶点。